Schott Pharma — Interim / Quarterly Report 2026

Feb 11, 2026

Quarterly Statement Q1 2026

for the period from October 1, 2025 to December 31, 2025

Contents

Financial factsheet	3
Business performance and key financial indicators	4
Report on changed forecasts	8
Consolidated statement of income	9
Consolidated statement of financial position	10
Consolidated statement of cash flows	12
Additional information	14

Financial factsheet

Q1 2026

October 1, 2025 – December 31, 2025

SCHOTT Pharma

Revenue bridge				Results of operations (in EUR m / in %)	Q1 2026	Q1 2025
(in EUR m)			Revenue	240.2	231.4
	+4.8%	-1.0%	+3.8%	Revenue growth at constant currencies	+4.8%	+4.8%
				High-value solutions (HVS) revenue share	57%	55%
			240.2	EBITDA	65.2	58.7
231.4	+11.2	-2.4		EBITDA margin	27.1%	25.4%
				EBIT	43.8	40.2
				EBIT margin	18.2%	17.4%
Q1 2025	Organic growth	FX	Q1 2026	Financial result	-1.8	-3.4
				Income tax expenses	-8.8	-7.0
				Profit for the period	33.3	29.8
	Revenue by region(in EUR m)		HVS revenue share(in %)	Earnings per share (in EUR)	0.22	0.20

Financial position (in EUR m)	Q1 2026	Q1 2025
Cash flows from operating activities	3.4	25.1
Cash flows from ongoing investing activities	-23.2	-21.0
Free cash flow	-19.8	4.1

Net assets (in EUR m / in %)	Dec. 31,2025	Sep. 30,2025
Working capital	244.1	199.3
Working capital in % of revenue	25.4%	20.2%
Equity ratio	57.3%	55.9%
Net debt	146.9	122.2

Employees	Dec. 31,2025	Sep. 30,2025
Headcount (as of the reporting date)	4,829	4,811

Drug Containment Solutions (DCS)

Revenue bridge(in EUR m)			Results of operations (in EUR m / in %)	Q1 2026	Q1 2025
	+9.4%-2.5%	+6.9%	Revenue	137.2	128.3
			EBITDA	33.4	28.1
128.3	-3.2+12.1	137.2	EBITDA margin	24.3%	21.9%
			EBIT	24.1	19.0
			EBIT margin	17.6%	14.8%

Drug Delivery Systems (DDS)

Revenue bridge(in EUR m)				Results of operations (in EUR m / in %)	Q1 2026	Q1 2025
	-0.8%	+0.8%	-0.0%	Revenue	103.1	103.1
				EBITDA	32.6	35.1
				EBITDA margin	31.6%	34.1%
				EBIT	20.7	25.9
103.1	-0.9	+0.8	103.1	EBIT margin	20.0%	25.1%

Business performance and key financial indicators

Preliminary remarks

The SCHOTT Pharma Group ("SCHOTT Pharma") financial year begins on October 1 and ends on September 30 of the following year. Q1 2026 therefore covers the period from October 1, 2025 to December 31, 2025. The period in the previous year (Q1 2025) referred accordingly to the period from October 1, 2024 to December 31, 2024.

Results of operations

SCHOTT Pharma generated revenue of EUR 240.2m in the first quarter of the financial year 2026, a year-onyear increase of 3.8%, and constant currency revenue growth of 4.8%. Growth was again largely driven by continued buoyant demand for High Value Solutions (HVS). The HVS revenue share rose two percentage points year-on-year to 57% matching the level seen in the financial year 2025.

Revenue performance by segment

			Change in %
(in EUR m)	Q1 2026	Q1 20251	Reported	Constantcurrencies
Drug Containment Solutions (DCS)	137.2	128.3	+6.9%	+9.4%
Drug Delivery Systems (DDS)	103.1	103.1	-0.0%	-0.8%
Consolidation/reconciliation	-0.1	-0.1	+75.5%	+75.5%
Total	240.2	231.4	+3.8%	+4.8%

1 Adjusted information for the previous year (see Consolidated statement of income).

Revenue in the Drug Containment Solutions (DCS) segment was up 6.9% (at constant currencies: 9.4%), driven mainly by the change to the product mix as a result of the significant increase in demand for readyto-use cartridges and the growth in special pharmaceutical vials. The vials have optimized inner surfaces, better geometric strength, low-friction outer coatings or special inner coatings and are therefore also suitable for more demanding applications.

Compared to the previous year, the Drug Delivery Systems (DDS) segment delivered a stable revenue performance; at constant currencies, a slight decline of -0.8%. The buoyant demand for prefillable glass syringes, met in particular by the new manufacturing capacities in Hungary, had a positive impact. In contrast, demand for polymer syringes softened with declining sales in mRNA modalities weighing on revenue performance.

Revenue performance by region

(in EUR m)	Q1 2026	Q1 20251	Changein %
EMEA	137.0	123.2	+11.3%
Asia and South Pacific	37.8	43.9	-14.1%
North America	43.2	43.9	-1.6%
South America	22.2	20.4	+9.0%
Total	240.2	231.4	+3.8%

1 Adjusted information for the previous year (see Consolidated statement of income).

SCHOTT Pharma's EBITDA was EUR 65.2m in the first quarter of the financial year 2026, thus exceeding the previous year's figure of EUR 58.7m. The EBITDA margin was 27.1% compared with 25.4% in the same period in the previous year.

EBITDA performance by segment

(in EUR m)	Q1 2026	Q1 20251	Changein %
Drug Containment Solutions (DCS)	33.4	28.1	+18.9%
Drug Delivery Systems (DDS)	32.6	35.1	-7.3%
Consolidation/reconciliation	-0.8	-4.5	-83.4%
Total	65.2	58.7	+11.1%

1 Adjusted information for the previous year (see Consolidated statement of income).

EBITDA in the DCS segment increased disproportionately to revenue performance, raising the EBITDA margin to 24.3% (Q1 2025: 21.9%). Alongside volume effects, the improved product mix – driven by the increased demand for HVS products – had a particularly positive impact. These effects offset the ramp-up costs associated with capacity relocations.

As expected, the DDS segment reported a decline in EBITDA. The EBITDA margin was 31.6% (Q1 2025: 34.1%). The decrease in demand for polymer syringes and the associated lower capacity utilization were key factors. Ramp-up costs associated with capacity expansions for glass syringes also impacted the result. The positive revenue performance for glass syringes was only able to partially offset these effects.

In the previous year, EBITDA was impacted by negative exchange rate effects, resulting in particular from the US dollar and the Swiss franc fluctuating against the euro, and relating to the valuation of foreign exchange forward contracts. Exchange rate effects recognized in profit or loss are presented under the "Consolidation/reconciliation" item. There were no similar exchange rate effects in the first quarter of the current financial year.

The Group's cost of sales was up 4.3% and therefore slightly disproportionate to revenue. The gross profit margin was 33.2% (Q1 2025: 33.5%). The slight decline is mainly due to a change to the product mix as well as lower capacity utilization for polymer syringes in the DDS segment.

The balance of other operating income and expenses was almost even at EUR +0.4m (Q1 2025: EUR -1.2m), mainly due to lower exchange rate losses year-on-year of EUR 3.4m, which in the previous year were primarily due to the valuation of foreign exchange forward contracts. These were offset by lower income from reimbursed costs, which was down EUR 3.0m year-on-year, and mainly includes income from research and development projects carried out for customers as well as other services provided to SCHOTT Group companies.

The financial result was up EUR +1.6m compared to Q1 2025 to EUR -1.8m, mainly due to lower interest expenses from cash pool financing as a result of intra-group debt restructuring in Q1 2026.

Income tax expenses amounted to EUR 8.8m, a year-on-year increase of EUR 1.7m. As profit before income taxes rose by EUR 5.2m, the tax rate increased from 19.1% to 20.8%, mainly due to a change in the country mix compared to the previous year – based on profit before income taxes.

Overall, the aforementioned performance resulted in profit for the period increasing by EUR 3.5m to EUR 33.3m. Earnings per share amounted to EUR 0.22 (Q1 2025: EUR 0.20).

Financial position

(in EUR m)	Q1 2026	Q1 20251	Change
Cash flows from operating activities	3.4	25.1	-21.7
Cash flows from investing activities	-43.7	-59.6	+15.9
Cash flows from financing activities	42.6	28.6	+14.0

1Adjusted information for the previous year (see Consolidated statement of cash flows).

SCHOTT Pharma posted positive cash flows from operating activities of EUR 3.4m in the first three months of the financial year 2026 (Q1 2025: EUR 25.1m). Operating income (EBIT) of EUR 43.8m (Q1 2025: EUR 40.2m) made a positive contribution, as did non-cash effective depreciation, amortization and impairment of non-current assets of EUR 21.4m (Q1 2025: EUR 18.5m). The increase in depreciation, amortization and impairment reflects the extensive capital expenditure in capacity expansions in recent financial years. Please refer to the "Results of operations" section for details of EBIT performance. The change in working capital had a negative impact on cash flows of EUR -44.7m (Q1 2025: EUR -17.1m). The main reason for this was the lower trade liabilities to third parties and SCHOTT Group. Liabilities as of September 30 usually include higher liabilities relating to capital expenditure in the fourth quarter, which are settled, as expected, in the first quarter of the following financial year. In contrast to the previous year, trade receivables had no offsetting effect; this was due to the postponement of payments from a major customer to the second quarter as of the reporting date. The change in provisions and accrued liabilities due to Christmas bonuses and other bonus payments in the first quarter of EUR -7.7m (Q1 2025: EUR -13.8m) also contributed to the reduction. In addition, tax payments reduced cash flows from operating activities by EUR -6.0m (Q1 2025: EUR -8.2m). The balance of interest received and paid led to cash outflows of EUR -0.3m in the first quarter of the financial year 2026 (Q1 2025: EUR -1.7m).

Cash flows from investing activities are broken down as follows:

(in EUR m)	Q1 2026	Q1 20251	Change
Cash flows from ongoing investing activities	-23.2	-21.0	-2.3
Cash flows from investment of liquid assets	-20.5	-38.6	+18.2
Cash flows from investing activities	-43.7	-59.6	+15.9

1Adjusted information for the previous year (see Consolidated statement of cash flows).

Cash flows from ongoing investing activities include cash inflows from disposals and cash outflows for capital expenditure on property, plant and equipment and intangible assets. The balance in the first quarter of the financial year 2026 amounted to EUR -23.2m, almost all of which was attributable to capital expenditure on property, plant and equipment and intangible assets. As a result, capital expenditure was slightly above the level in the previous year. Capital expenditure was allocated to capacity expansion projects in both segments, particularly at the locations in Switzerland and Hungary.

Cash flows from investment of liquid assets mainly comprise changes in financial receivables – SCHOTT Group, resulting from cash pool receivables vis-à-vis SCHOTT Group. These led to cash outflows of EUR -20.9m in the first quarter of the financial year 2026 (Q1 2025: EUR -38.6m), mainly due to the positive free cash flow of our Group companies in Germany, the USA and Mexico, which was invested in the SCHOTT Group as part of cash pool and treasury management.

Cash flows from financing activities led to cash inflows of EUR 42.6m in the first quarter of the financial year 2026 (Q1 2025: EUR 28.6m). Significant cash inflows of EUR 47.2m (Q1 2025: EUR 34.1m) resulted from the change in financial liabilities – SCHOTT Group, i.e. essentially from cash pool liabilities vis-à-vis SCHOTT Group. The cash inflows were due to the increased financing needs of individual Group companies for ongoing capacity expansion projects. These inflows were offset by cash outflows of EUR -3.7m (Q1 2025: EUR -3.4m) from the allocation of plan assets and of EUR -0.9m (Q1 2025: EUR -2.1m) from the repayment of lease liabilities.

All in all, the increase in cash and cash equivalents was EUR 2.3m – based on the position as of the reporting date of September 30, 2025. Taking into account changes due to foreign exchange rates of EUR -0.2m, cash and cash equivalents amounted to EUR 24.6m as of December 31, 2025.

Net assets

As of December 31, 2025, SCHOTT Pharma's non-current assets were up EUR 11.5m to a total of EUR 928.8m. This increase was mainly due to the EUR 6.8m growth in the balance of intangible assets and property, plant and equipment. Capital expenditure of EUR 23.7m was offset by depreciation, amortization and impairment of EUR 21.4m and disposals of assets of EUR 0.2m. In addition, exchange rate effects resulted in an increase of EUR 4.5m, while inflationary adjustments at our Argentinian subsidiary resulted in a further increase of EUR 0.2m. Capital expenditure served to expand manufacturing capacities in both segments. In addition, the positive performance of our joint ventures led to a EUR 3.9m increase in the valuation of investments accounted for using the equity method.

Current assets were up EUR 17.6m compared with September 30, 2025. This increase was mainly driven by a EUR 21.3m increase in financial receivables – SCHOTT Group, which is largely attributable to the positive free cash flow of our Group companies in Germany, the USA and Mexico. This was offset by a EUR 2.4m decrease in the balance of contract assets and trade receivables from third parties and SCHOTT Group. In particular the reduction in stocks of customer-specific products in the DDS segment led to a decrease in contract assets.

SCHOTT Pharma's equity amounted to EUR 932.3m as of the reporting date (September 30, 2025: EUR 893.7m) and the equity ratio increased from 55.9% to 57.3% as of the reporting date. The higher ratio is the combined result of a EUR 29.1m increase in total assets and a EUR 38.6m increase in equity. Please refer to the relevant statements in the section below for more details on the increase in total assets. At EUR 33.3m, profit for the period in the first three months of the financial year was the main factor driving the increase in equity, as well as actuarial gains of EUR 2.8m in connection with changes in the interest rates relevant to the measurement of pension provisions. In addition, foreign currency translation effects of EUR 2.5m had a positive impact on equity.

At EUR 252.7m, long-term debt was roughly at the same level as in the previous year (September 30, 2025: EUR 251.0m). While income tax provisions were up EUR 6.3m, pension provisions were down EUR 4.9m. The change in pension provisions is due to the allocation of plan assets and changes in the interest rate relevant in terms of measurement.

Compared with September 30, 2025, current liabilities were down EUR 11.1m to EUR 442.7m. The main driver of this decrease was the reduction in trade liabilities to third parties and SCHOTT Group of EUR 40.1m. As of the previous year's reporting date, liabilities included higher amounts related to capital expenditure in the fourth quarter, which were settled at the beginning of the current financial year. In addition, accrued liabilities were down EUR 15.4m, in particular due to the Christmas bonuses and other bonus payments to employees in the first quarter. This was offset by an increase of EUR 48.6m in financial liabilities – SCHOTT Group. The key drivers here were the increased financing needs for ongoing capacity expansion projects of individual Group companies.

Report on changed forecasts

We confirm our forecast made in the Annual Report 2025.

Key financial performance indicator	ForecastFinancial year 2026	BasisFinancial year 2025
Organic revenue growth	between 2% and 5%	EUR 986.2m
EBITDA margin	around 27%	28.4%

Detailed information on the forecasts for the financial year 2026 can be found in the Combined management report in the Annual Report 2025, beginning on page 37.

The risk and opportunity position has not changed significantly since September 30, 2025. Taking all planned or implemented measures into account, there were no identifiable risks at the time of reporting that would individually or collectively jeopardize SCHOTT Pharma's existence as a going concern. Detailed information on SCHOTT Pharma's risk management system and the risk and opportunity position can be found in the Combined management report in the Annual Report 2025 beginning on page 39.

Our forecast is based on various assumptions. In terms of revenue growth, it excludes portfolio measures but assumes that exchange rates will remain constant. Furthermore, it assumes that the geopolitical and global economic situation, global supply chains, inflation and energy supply will not deteriorate, and that there will be no further relevant pandemic-related restrictions.

SCHOTT Pharma's actual performance may deviate positively or negatively from our forecasts, either due to the risks and opportunities described in the Annual Report 2025 (chapter entitled "Report on risks and opportunities" in the Combined management report), or because our expectations and assumptions fail to materialize.

Mainz, February 9, 2026

SCHOTT Pharma AG & Co. KGaA Represented by the Management Board of SCHOTT Pharma Management AG

Andreas Reisse Reinhard Mayer

Consolidated statement of income

for the period from October 1, 2025 to December 31, 2025

(in EUR k)	Q1 2026	Q1 20251
Revenue	240,188	231,368
Cost of sales	-160,438	-153,895
Gross profit	79,750	77,473
Selling expenses	-21,471	-20,965
General administrative expenses	-12,257	-11,541
Research and development costs	-7,342	-7,074
Other operating income	2,713	6,033
Other operating expenses	-2,347	-7,228
Share of profit from investments accounted for using the equity method	4,747	3,464
Operating income (EBIT)	43,793	40,162
Interest income	2,330	2,138
Interest expenses	-4,001	-4,802
Net other financial result	-79	-682
Financial result	-1,750	-3,346
Profit before income taxes	42,043	36,816
Income tax expenses	-8,762	-7,036
Profit for the period	33,281	29,780
thereof attributable to non-controlling interests	101	91
thereof attributable to limited liability shareholders of SCHOTT Pharma KGaA	33,180	29,689
Earnings per share (in EUR), based on the share of profitfor the period attributable to limited liability shareholders of SCHOTT Pharma KGaA
Basic	0.22	0.20
Diluted	0.22	0.20

1 Adjusted information for the previous year – retrospective adjustment of revenue, cost of sales and income tax expenses as certain products were included in revenue recognized over time, although the requirements in accordance with IFRS 15.35(c) were not met in full. As a result, revenue was up EUR 1,527k, cost of sales EUR -621k and income tax expenses EUR -111k. Additional details are provided in Note 3.5 of the notes to the consolidated financial statements in the Annual Report 2025.

Consolidated statement of financial position

as of December 31, 2025

Assets
(in EUR k)	Dec. 31, 2025	Sep. 30, 2025
Intangible assets	29,779	29,689
Property, plant and equipment	792,352	785,673
Investments accounted for using the equity method	92,374	88,498
Deferred tax assets	14,048	13,042
Other financial assets	1	1
Other non-financial assets	231	342
Non-current assets	928,785	917,245
Inventories	182,526	174,975
Contract assets	73,742	79,746
Trade receivables	199,681	195,263
Trade receivables – SCHOTT Group	5,314	6,095
Financial receivables – SCHOTT Group	176,446	155,103
Income tax assets	7,156	10,458
Other financial assets	7,546	11,396
Other non-financial assets	21,999	25,895
Cash and cash equivalents	24,587	22,470
Current assets	698,997	681,401
Total assets	1,627,782	1,598,646

Equity and liabilities

(in EUR k)	Dec. 31, 2025	Sep. 30, 2025
Subscribed capital	150,615	150,615
Capital reserves	494,481	494,481
Generated Group equity	315,738	279,787
Accumulated other Group equity	-30,662	-33,100
Equity attributable to limited liability shareholders of SCHOTT Pharma KGaA	930,172	891,783
Non-controlling interests	2,149	1,966
Equity	932,321	893,749
Provisions for pensions and similar commitments	18,700	23,573
Provisions for income taxes	9,201	2,902
Other provisions	6,349	6,656
Deferred tax liabilities	22,574	21,989
Contract liabilities	117,529	116,700
Other financial liabilities	78,393	79,226
Non-current liabilities	252,746	251,046
Other provisions	9,859	9,917
Accrued liabilitiesContract liabilities	33,67525,490	49,07626,314
Trade liabilities	43,827	73,305
Trade liabilities – SCHOTT Group	19,987	30,574
Financial liabilities – SCHOTT Group	268,552	219,953
Income tax liabilities	16,659	22,498
Other financial liabilities	5,295	6,371
Other non-financial liabilities	19,371	15,843
Current liabilities	442,715	453,851
Total equity and liabilities	1,627,782	1,598,646

Consolidated statement of cash flows

for the period from October 1, 2025 to December 31, 2025

(in EUR k)	Q1 2026	Q1 20251,2
Profit for the period	33,281	29,780
Depreciation, amortization and impairment as well as impairment reversals on non-current assets	21,412	18,535
Changes in provisions and accrued liabilities	-7,740	-13,849
Other non-cash income/expenses	-5,098	-1,325
Net gain or loss on the disposal of intangible assets and property, plant and equipment	-48	4
Net gain or loss from financial assets	-84	-359
Changes in inventories and advance payments made on inventories	-6,208	-10,565
Changes in contract assets	6,004	-11,461
Changes in trade receivables	-3,870	23,917
Changes in trade receivables – SCHOTT Group	932	736
Changes in other assets	10,805	6,378
Changes in contract liabilities	-994	-3,103
Changes in trade liabilities	-29,906	-15,879
Changes in trade liabilities – SCHOTT Group	-10,673	-741
Changes in other liabilities	-3,529	4,690
Changes in deferred taxes	-885	-1,684
Cash flows from operating activities (A)	3,399	25,074
Cash inflows from the sale of property, plant and equipment	203	171
Purchase of property, plant and equipment	-23,414	-21,086
Purchase of intangible assets	-24	-41
Cash flows from ongoing investing activities	-23,235	-20,956
Cash inflows from the sale of financial assets	889	0
Purchase of financial assets	-475	0
Changes in financial receivables – SCHOTT Group	-20,886	-38,616
Cash flows from investing activities (B)	-43,707	-59,572
Changes in financial liabilities – SCHOTT Group	47,171	34,080
Cash outflows from allocation to plan assets	-3,671	-3,358
Cash outflows from repayments of outstanding lease liabilities	-913	-2,089
Cash flows from financing activities (C)	42,587	28,633

(in EUR k)	Q1 2026	Q1 2025
Net change in cash and cash equivalents (A+B+C)	2,279	-5,865
Cash and cash equivalents at beginning of the period	22,470	23,182
- Cash on hand	1	3
- Bank deposits	22,469	23,179
Change in cash and cash equivalents due to foreign exchange rates	-162	-539
Cash and cash equivalents at end of the period	24,587	16,778
- Cash on hand	5	6
- Bank deposits	24,582	16,772

Additional notes to the consolidated statement of cash flows3
Interest paid	-2,643	-3,829
Interest received	2,330	2,138
Income tax expenses paid	-6,017	-8,234

1 Adjusted information for the previous year – retrospective adjustment within cash flows from operating activities as certain products were included in revenue recognized over time, although the requirements in accordance with IFRS 15.35(c) were not met in full. As a result, there were movements between individual items, but without this having an impact on total cash flows from operating activities. Additional details are provided in Note 3.5 of the notes to the consolidated financial statements in the Annual Report 2025.

2 Adjusted information for the previous year – reclassifications from cash flows from financing activities: the item Change in financial receivables – SCHOTT Group has been reported within cash flows from investing activities since the financial year 2025. Previously, allocation to cash flows from financing activities was based on an economic perspective; a legal approach will be applied going forward. As a result, cash flows from investing activities were down EUR -38,616k. In addition, cash flows related to financial assets and financial liabilities have been reclassified and from this point forward will be allocated to cash flows from operating activities. This led to an increase in cash flows from operating activities of EUR 700k. Cash flows from financing activities increased by a total of EUR 37,916k. Additional details are provided in Note 33 of the notes to the consolidated financial statements in the Annual Report 2025.

3 Included in cash flows from operating activities.

13

Additional information

Financial calendar

Date	Event
May 13, 2026	Publication of Half-Year Financial Report as of March 31, 2026
August 12, 2026	Publication of Quarterly Statement as of June 30, 2026
December 10, 2026	Publication of Annual Report 2026

Disclaimer/forward-looking statements

This Quarterly Statement contains forward-looking statements which are based on the Company's assumptions, expectations and intentions. Such statements are indicated by words such as "expect", "assume", "intend" or similar wording, and are based both on the information currently available to management and on the prevailing environment. These may change at any time. The Company assumes no liability for the correctness and accuracy of any expectations or assumptions expressed in this statement. The Company also undertakes no obligation to update any of its forward-looking statements to bring them in line with actual developments after this Quarterly Statement has been published.

Publication

This Quarterly Statement was published on February 11, 2026. The document is also available in German. In the event of any discrepancies, the German version shall be authoritative and prevail over the English translation.

In the interest of sustainability, the Company's quarterly statements are not available in printed form. All quarterly statements are available online for download in PDF format.

Rounding and language

Due to rounding, individual figures in this document and in other documents may not correspond exactly to the totals stated, and percentages shown may not exactly reflect the absolute values to which they relate.

Imprint

SCHOTT Pharma AG & Co. KGaA Hattenbergstraße 10 55122 Mainz, Germany

www.schott-pharma.com

Contact

Tobias Erfurth Head of Investor Relations

Jasko Terzic Senior Investor Relations Manager

Email: ir.pharma@schott.com